2013

  • Broadview Ventures adds New Members to SAB

    September 16, 2013

    September 16, 2013: Broadview Ventures adds new members to its Strategic Advisory Board. Joseph Loscalzo, M.D., Ph.D. and Argeris “Jerry” Karabelas, Ph.D., join the Strategic Advisory Board of Broadview Ventures. Broadview’s mission is to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments to support early stage ventures. “We are excited to add Dr. Loscalzo and Dr. Karabelas to our Strategic Advisory Board,” stated Christopher H. Colecchi, Managing Director. “Their combined experience adds breadth and depth a

    Read More
  • BioKier Receives Investment from Broadview Ventures and AHA

    July 24, 2013

    July 24, 2013: BioKier, a privately held development-stage pharmaceutical company focused on the treatment of diabetes, announced today that it has closed on a funding commitment of $1.7 million from Broadview Ventures and the American Heart Association’s Science & Technology Accelerator Program. This is the first institutional venture capital investment for BioKier, which has previously received seed funding from individuals and a Small Business Research Loan from the North Carolina Biotechnology Center.   Press Release

    Read More
  • CellAegis Devices, Inc. announces 1st Clinical Trial in EU

    May 2, 2013

    May 2, 2013: CellAegis Devices, Inc., announced today the first clinical trial program in the European Union to evaluate the use of the Company’s autoRIC™ Device for Chronic Remote Ischemic Conditioning (CRIC). In the DREAM study (Daily REmote Ischemic Conditioning following Acute Myocardial INfarction), a University of Leicester-sponsored Phase II, randomized, placebo-controlled clinical study, CRIC will be evaluated for its ability to prevent negative remodeling of the heart in patients following an acute myocardial infarction. A quarter of patients suffering a heart attack show symptoms

    Read More
  • VentriNova, Inc. presenting at TEDMED 2013

    April 16, 2013

    April 16, 2013:  VentriNova, Inc., a cardiac regenerative medicine biotechnology company, announced today that Dr. Hina Chaudhry, Founder, will be presenting VentriNova at the TEDMED 2013 conference April 16-19, 2013 as part of the TEDMED Hive for the most innovative startup companies in healthcare.  The meeting takes place at the John F. Kennedy Center for the Performing Arts in Washington, D.C., and it will also be available online at www.TEDMED.com. Press Release  

    Read More
  • CellAegis Devices, Inc. Receives Marketing Authorization

    March 7, 2013

    March 7, 2013: CellAegis Devices, Inc., announced today that it has received marketing authorization from Health Canada that allows for the commercial introduction in Canada of the Company’s autoRIC™ Device for Remote Ischemic Conditioning (RIC). Health Canada has granted a Medical Device Class III license for use of the autoRIC Device to provide non-invasive RIC for adult patients undergoing cardiothoracic surgery or interventional cardiothoracic procedures, as well as for patients with evolving myocardial infarction.   Press Release

    Read More
  • CellAegis Devices, Inc. receives Investigational Testing Approval from Health Canada

    February 27, 2013

    February 27, 2013: CellAegis Devices, Inc., announced today that it has received an Investigational Testing Approval (ITA) from Health Canada that allows the initiation of clinical testing in Canada of the Company’s autoRICTM Device for Chronic Remote Ischemic Conditioning (CRIC). In a Canadian Institutes of Health Research (CIHR-sponsored Phase II, randomized, double-blind, placebo-controlled, multi-center clinical study, CRIC will be evaluated for its ability to reduce adverse left ventricular remodeling following primary percutaneous coronary intervention (PCI) for St-segment elevation my

    Read More
  • DecImmune Therapeutics Raises $2.25M

    February 26, 2013

    February 26, 2013: DecImmune Therapeutics announced today that it has completed a $2.25 million equity financing.  The financing is from a new investor Broadview Ventures, along with existing investors Astellas Venture Management and HealthCare Ventures.   The new funds will enable rapid advancement toward IND filing for the company’s proprietary antibody therapeutic to reduce tissue damage and improve ventricular function associated with myocardial infarction.   DecImmune-Financing-Press-Release

    Read More